Bleselumab (ASKP 1240), a human anti-CD40 monoclonal antibody (mAb), exhibits high-affinity binding to CD40 (Kd: 0.24 nM) and hinders immune responses by impeding the CD40-CD40L interaction, thereby preventing organ transplant rejection [1].

Bleselumab（0-1 μg/mL，48小时）剂量依赖性地抑制了可溶性CD154[2]诱导的外周血单核细胞（PBMCs）增殖。

Bleselumab（0.1-10 mg/kg，静脉注射）抑制食蟹猴的迟发型超敏反应（DTH）[2]。Bleselumab（2 mg/kg，静脉注射）延长食蟹猴肾脏异体移植存活时间[3]。结合他克莫司，Bleselumab（2或5 mg/kg，静脉注射）的中位生存时间（MST）较单药疗法更长[3]。